Coherus Oncology (CHRS) Price to Book (2014 - 2026)

Coherus Oncology has disclosed Price to Book across 13 years of filings, most recently posting 3.55 for Q2 2026.

• In Q2 2026, Price to Book rose 402.04% year-over-year to 3.55; the TTM figure through Jun 2026 stood at 3.55 (up 402.04% YoY), while the FY2025 annual figure was 2.82, up 333.26% from the prior year.
• Price to Book came in at 3.55 for Q2 2026 at Coherus Oncology, up from 3.31 in the prior quarter.
• In the past five years, Price to Book ranged from a high of 79.47 in Q1 2022 to a low of 24.86 in Q2 2022.
• Average Price to Book over 5 years is 2.0, with a median of 1.65 recorded in 2023.
• The largest YoY upside for Price to Book was 849.76% in 2022 against a maximum downside of 467.25% in 2022.
• Over 5 years, Price to Book stood at 4.54 in 2022, then surged by 57.49% to 1.93 in 2023, then surged by 37.43% to 1.21 in 2024, then soared by 333.26% to 2.82 in 2025, then increased by 26.07% to 3.55 in 2026.
• Per Business Quant data, the three most recent Price to Book figures were 3.55 in Q2 2026, 3.31 in Q1 2026, and 2.82 in Q4 2025.